Drug Trial Radar · NCT03635996
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
Last checked: Nov 20, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
169
Actual
Start
Dec 10, 2018
Primary completion
Nov 13, 2020
Study completion Nov 13, 2020
Sponsor
- Lead sponsor
- Milestone Pharmaceuticals Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medpace, Inc.
- First posted
- Aug 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety of etripamil nasal spray (NS) 70 mg when self-administered by patients with an episode of Paroxysmal Supraventricular Tachycardia in an outpatient setting (i.e., without medical supervision).
Conditions
- Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil NS 70 mgDrug
All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug.
Aptar Pharma Nasal Spray Bidose SystemDevice
Patients will self-administer the study drug using the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Conversion of an Episode of PSVT to Sinus Rhythm (SR) After Study Drug Administration.Time frame: 18 months
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
Arizona Arrhythmia Research Center
Phoenix, Arizona
Arkansas Cardiology
Little Rock, Arkansas
Los Alamitos Cardiovascular
Los Alamitos, California
South Denver Cardiology Associates, P.C
Littleton, Colorado
Baptist Health Ambulatory Services
Jacksonville, Florida
Mayo Clinic - Jacksonville
Jacksonville, Florida
Edgewater Medical Research
New Smyrna Beach, Florida
Piedmont Heart Institute
Atlanta, Georgia
Columbus Regional Research Institute
Columbus, Georgia
Georgia Arrythmia Consultants&Research Institute
Macon, Georgia
Iowa Heart Center
West Des Moines, Iowa
MedStar Health Research Institute
Baltimore, Maryland
Mayo Clinic
Rochester, Minnesota
Atlantic Health System - Morristown Medical Center
Morristown, New Jersey
Trinity Medical WNY, PC
Buffalo, New York
Weill Cornell Medical Center
New York, New York
The Presbyterian Hospital DBA Novant Health Heart and Vascular Institute
Charlotte, North Carolina
Heart House Research Foundation, LLC
Springfield, Ohio
Black Hills Cardiovascular Research
Rapid City, South Dakota
Baylor College of Medicine
Houston, Texas
Baylor Scott and White Research Institute - Round Rock
Round Rock, Texas
IHC Health Services Inc. DBA Intermountain Medical Center
Murray, Utah
Libin Cardiovascular Institute of Alberta - University of Calgary
Calgary, Alberta, Canada
Royal Alexandra Hospital
Edmonton, Alberta, Canada
Vancouver General Hospital - Research Institute ; Gordon and Leslie Diamond Health Centre
Vancouver, British Columbia, Canada
Victoria Cardiac Arrhythmia Trials, Inc.
Victoria, British Columbia, Canada
University of Manitoba, St Boniface General Hospital
Winnipeg, Manitoba, Canada
Cambridge Cardiac Care Centre
Cambridge, Ontario, Canada
Dawson Road Medical Centre
Guelph, Ontario, Canada
Hamilton Health Sciences
Hamilton, Ontario, Canada
Partners in Advanced Cardiac Evaluation (PACE) Cardiology Clinic
Newmarket, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Montreal Heart Institute - Institut de Cardiologie de Montréal
Montreal, Quebec, Canada
CIUSSS de l'Estrie - CHUS ; Hôpital Fleurimont
Sherbrooke, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.